Promising Future for CVRx: Buy Rating Supported by BENEFIT-HF Trial and Market Expansion
I'm PortAI, I can summarize articles.
William Blair analyst Brandon Vazquez maintains a Buy rating on CVRx stock, citing the BENEFIT-HF trial's potential to expand the U.S. market for heart failure patients and generate significant revenue. The trial could triple the total addressable market and, if CMS reimburses the Barostim device, add up to $50 million in revenue. Despite early-stage risks, the stock's valuation supports a positive outlook. Canaccord Genuity also reiterated a Buy rating with an $11.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments